These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21452543)

  • 1. [Risk of HBV reactivation under chemotherapy and immunosuppressants].
    Belle A; Bronowicki JP
    Rev Prat; 2011 Jan; 61(1):52-4. PubMed ID: 21452543
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
    Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
    Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention and management of hepatitis B virus reactivation during anticancer or immunosuppressive therapy].
    Oketani M; Tsubouchi H
    Nihon Rinsho; 2011 May; 69 Suppl 4():520-5. PubMed ID: 22096973
    [No Abstract]   [Full Text] [Related]  

  • 4. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
    Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection].
    Sato K
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):161-8. PubMed ID: 21368477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
    Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
    Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
    Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
    J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
    Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ
    J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis.
    Yeo W; Chan PK; Chan HL; Mo FK; Johnson PJ
    J Med Virol; 2001 Nov; 65(3):473-7. PubMed ID: 11596081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.
    Coiffier B
    Cancer Invest; 2006; 24(5):548-52. PubMed ID: 16939967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
    Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
    J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine for chemotherapy-induced reactivation of HBV: prophylaxis or treatment?
    Mancuso A; Pagliaro L
    Am J Gastroenterol; 2002 May; 97(5):1268-9. PubMed ID: 12014746
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management.
    Lubel JS; Testro AG; Angus PW
    Intern Med J; 2007 Oct; 37(10):705-12. PubMed ID: 17894766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention.
    Mindikoglu AL; Regev A; Schiff ER
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1076-81. PubMed ID: 16861051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From a medical mistake to a clinical warning: the case of HBV mutant virus reactivation in haematological patients.
    Zoppoli G; Bruzzone B; Caligiuri P; Picciotto A; Balleari E; Bruzzone A; Icardi G; Ghio R
    Br J Haematol; 2009 Mar; 144(6):969-70. PubMed ID: 19120363
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chemotherapy and immunosuppression in patients with hepatitis B or C].
    Sitruk V; Fain O; Gordien E; Ganne-Carrié N; Deny P; Beaugrand M; Trinchet JC
    Gastroenterol Clin Biol; 2001 Nov; 25(11):1002-7. PubMed ID: 11845054
    [No Abstract]   [Full Text] [Related]  

  • 17. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
    Ahmed A; Keeffe EB
    Am J Gastroenterol; 1999 Jan; 94(1):249-51. PubMed ID: 9934765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients.
    Watanabe M; Shibuya A; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Koizumi W
    Eur J Intern Med; 2010 Aug; 21(4):333-7. PubMed ID: 20603047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.
    Lubel JS; Angus PW
    J Gastroenterol Hepatol; 2010 May; 25(5):864-71. PubMed ID: 20546439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
    Cheng AL; Hsiung CA; Su IJ; Chen PJ; Chang MC; Tsao CJ; Kao WY; Uen WC; Hsu CH; Tien HF; Chao TY; Chen LT; Whang-Peng J;
    Hepatology; 2003 Jun; 37(6):1320-8. PubMed ID: 12774010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.